TheEdgeResearch
Home / Stocks / IAGX

Imagenetix, Inc. (IAGX)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▲ +0.00%
Market Cap
$5,685
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.66
52-Wk Range
0.0001-0.0002
CEO
Decky Goodrich
Country
US
Currency
USD

Imagenetix, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $5,685. On trailing twelve-month figures it carries a trailing P/E of -0.25, a net margin of -2.6%. Its beta of 0.66 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.25
Price / Sales
0.01
Price / Book
0.00
EV / EBITDA
-3.20
Gross margin
41.6%
Operating margin
1.7%
Net margin
-2.6%
Return on equity
Debt / equity
0.00
Current ratio
0.69
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
5
IPO date
2000-03-23
Headquarters
San Diego, CA, US
About Imagenetix, Inc.

Established in 1996 and headquartered in San Diego, California, Imagenetix, Inc. focuses on the creation, manufacturing, and distribution of distinctive, natural-ingredient nutritional supplements, as well as non-prescription topical creams and skincare solutions. Its flagship product, Celadrin, is a specialized formulation aimed at promoting joint well-being. The company also extends its business by licensing its proprietary technologies to third parties. Imagenetix reaches its customer base through a wide range of marketing avenues, encompassing direct and large-scale marketing enterprises, health and nutritional periodicals, medical and wellness professionals, and direct-response campaigns across radio and television.

Comparable companies

Imagenetix, Inc. is most often compared with the following Healthcare names:

BZAMFCANQFCVHIFGBIMNLVVFNTIIQMDTSYUPSYVCTRGM
More research on IAGX
IAGX technical analysis IAGX TheEdge Score Compare against peers
Open full interactive analysis & DCF →